Delivery Order SPE2DB22D9206-SPE2DB25FV5EB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a specific fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. No...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract, valued at $12,934.05, to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 40 mg capsules. DMS Pharmaceutical Group holds an Indefinite Delivery Vehicle (IDV) contract, valued up to $4,999,999, with DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a broad range of pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $4,311.35 contract is for the delivery of Xtandi 40 mg capsules and has a completion date of June 26, 2024. This order is issued under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with the DLA, which supports the recurring pharmaceutical supply needs of military health facilities...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). The contract, awarded on July 23, 2025, with a completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single-transaction fulfillment of pharmaceutical inventory...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 4,565,440,973 units of the pharmaceutical Xtandi 40 mg capsule. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
- The Defense Logistics Agency awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between the agency and the vendor. The award carries no...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $32,873.49 contract is for the delivery of 120-count capsules of the prescription drug Xtandi 40 mg. This delivery order contract is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which allows the DLA...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $10,222.72, is scheduled for completion by July 31, 2025, and was issued on July 30, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. This...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules in quantities of 120 units. This $17,245.40 firm fixed-price delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, and carries no set-aside designation. The order falls under DMS Pharmaceutical Group's existing single-award Indefinite...
- SPE2DB22D9206Indefinite Delivery Contract
- SPE2DB22D9206-SPE2DB25FV5EBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group maintains a substantial federal contracting footprint as a critical supplier within the military pharmaceutical supply chain, having consistently secured contracts for oncology treatments, specialty medications, and other pharmaceuticals since its SAM.gov registration in 2001. The company's core business involves distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare facilities. This particular delivery order for Xtandi—a prescription oncology medication—exemplifies the company's ongoing role in supplying specialized pharmaceutical products to support medical operations across Department of Defense healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 8/12/25 |